Article

Prediction of the 10-year course of borderline personality disorder.

Laboratory for the Study for Adult Development, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA.
American Journal of Psychiatry (Impact Factor: 13.56). 06/2006; 163(5):827-32. DOI: 10.1176/appi.ajp.163.5.827
Source: PubMed

ABSTRACT The purpose of this study was to determine the most clinically relevant baseline predictors of time to remission for patients with borderline personality disorder.
A total of 290 inpatients meeting criteria for both the Revised Diagnostic Interview for Borderlines and DSM-III-R for borderline personality disorder were assessed during their index admission with a series of semistructured interviews and self-report measures. Diagnostic status was reassessed at five contiguous 2-year time periods. Discrete survival analytic methods, which controlled for baseline severity of borderline psychopathology and time, were used to estimate hazard ratios.
Eighty-eight percent of the patients with borderline personality disorder studied achieved remission. In terms of time to remission, 39.3% of the 242 patients who experienced a remission of their disorder first remitted by their 2-year follow-up, an additional 22.3% first remitted by their 4-year follow-up, an additional 21.9% by their 6-year follow-up, an additional 12.8% by their 8-year follow-up, and another 3.7% by their 10-year follow-up. Sixteen variables were found to be significant bivariate predictors of earlier time to remission. Seven of these remained significant in multivariate analyses: younger age, absence of childhood sexual abuse, no family history of substance use disorder, good vocational record, absence of an anxious cluster personality disorder, low neuroticism, and high agreeableness.
The results of this study suggest that prediction of time to remission from borderline personality disorder is multifactorial in nature, involving factors that are routinely assessed in clinical practice and factors, particularly aspects of temperament, that are not.

0 Bookmarks
 · 
65 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Borderline personality disorder is estimated to be present in approximately 6% of outpatient primary care settings. However, the time and energy spent on this population can greatly exceed what primary care doctors are able to spend. This article gives an overview of borderline personality disorder, including the clinical characteristics, epidemiology, and comorbidities, as well as pharmacologic and most important behavioral management. It is our hope that, with improved understanding of the disorder and skills for managing this population, caring for patients with the disorder can be more satisfying and less taxing for both primary care doctors and their patients.
    Medical Clinics of North America 09/2014; 98(5):1049–1064. · 2.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aunque continúa siendo motivo de debate, casi sin ninguna duda el pronóstico de los trastornos depresivos se agrava con la presencia de un trastorno comórbido de la personalidad. Este hallazgo es intuitivo pero no aceptado por todos los investigadores que trabajan en este campo. En parte, esto podría deberse a las dificultades en el diseño y la interpretación de los estudios de investigación sobre ambos procesos, las dificultades para evaluar transversalmente los trastornos de la personalidad en relación con la depresión, la naturaleza variable tanto de la depresión como los trastornos de la personalidad y los factores etiológicos similares para ambos procesos. A esto se debe añadir que este pronóstico más desfavorable se observa con independencia del tipo de intervención utilizada para tratar la depresión. No se dispone de estudios que hayan examinado programas de tratamiento específico para ambos procesos, instaurados de forma paralela, lo que dificulta la separación de los efectos del tratamiento de los trastornos depresivos de los marcadores de rasgo de los pacientes. El tratamiento de pacientes con comorbilidades requiere una estrategia terapéutica diseñada individualmente que tenga en cuenta la gravedad de cada entidad y su influencia en la función social y la psicopatología. La depresión ha de tratarse de manera agresiva y es probable que las intervenciones específicas dirigidas a la influencia del trastorno de la personalidad se traduzcan en mejoras. Puede ser que la duración del tratamiento tenga que ser más prolongada, al igual que en el caso de numerosos procesos duales. Es necesario realizar investigaciones que clarifiquen la interrelación de ambos procesos. Las claras diferencias en las clasificaciones clínicas actuales y los marcos de tiempo de ambos procesos, en comparación con los hallazgos de investigación hasta la fecha, dificultan esta investigación.
    Psiquiatría Biológica. 12/2008; 15(6):223-227.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psychotherapies are currently the front-line approach to treating individuals with comorbid post-traumatic stress disorder (PTSD) and borderline personality disorder (BPD). Of the available psychotherapeutic treatment options, those that have been evaluated in randomized controlled trials (RCTs) and shown to be efficacious in reducing PTSD among individuals with BPD include: Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), Dialectical Behavior Therapy (DBT), DBT for PTSD (DBT-PTSD), and DBT with the DBT Prolonged Exposure protocol (DBT + DBT PE). In addition, Narrative Exposure Therapy (NET) has shown preliminary evidence of effectiveness in an open trial. The available research indicates that individuals with a primary diagnosis of PTSD and mild or sub-threshold BPD (e.g., without suicidal or serious self-injurious behavior or other severe comorbidities) can be effectively treated via brief (9–14 session), single-diagnosis treatments such as PE and CPT that focus solely on treating PTSD. PE and CPT appear to be comparably efficacious for individuals with PTSD and mild BPD. Individuals with PTSD and a moderate level of BPD (e.g., active non-suicidal self-injury [NSSI] without recent life-threatening behavior, some significant comorbidities) have shown good outcomes in DBT-PTSD, a 12-week, residential, phase-based treatment that targets comorbid problems (e.g., emotion dysregulation, psychosocial impairment) before and after addressing PTSD. Finally, individuals with PTSD and a severe level of BPD (e.g., with recent and/or acute suicidal behavior, serious NSSI and multiple severe comorbidities) have been effectively treated in longer-term (one year), integrated treatments such as DBT and DBT + DBT PE that concurrently target BPD, PTSD, and other related problems. Of these integrated treatments, DBT + DBT PE appears to be more efficacious than DBT alone in improving PTSD, suicidal and self-injurious behavior, and other trauma-related outcomes among severe BPD patients.
    Current Treatment Options in Psychiatry. 12/2014; 1(4).